These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9819812)

  • 1. Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys.
    Coscarella A; Liddi R; Bach S; Zappitelli S; Urso R; Mele A; De Santis R
    Mol Biotechnol; 1998 Oct; 10(2):115-22. PubMed ID: 9819812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys.
    Coscarella A; Liddi R; Di Loreto M; Bach S; Faiella A; van der Meide PH; Mele A; De Santis R
    Cytokine; 1998 Dec; 10(12):964-9. PubMed ID: 10049520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant human granulocyte-macrophage colony stimulating factor on hematopoiesis in normal cynomolgus monkeys.
    Aramaki K; Yanagida M; Kikumori M; Kojima M; Suzuki T; Amano K
    J Vet Med Sci; 1993 Apr; 55(2):221-5. PubMed ID: 7685638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effects of granulocyte-macrophage colony stimulating factor with erythropoietin in subhuman primates.
    Krumwieh D; Siebold B; Weinmann E; Seiler FR
    Am J Clin Oncol; 1991; 14 Suppl 1():S1-4. PubMed ID: 2048558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
    Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
    Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
    Miller LL; Korn EL; Stevens DS; Janik JE; Gause BL; Kopp WC; Holmlund JT; Curti BD; Sznol M; Smith JW; Urba WJ; Donegan SE; Watson TM; Longo DL
    Blood; 1999 May; 93(10):3250-8. PubMed ID: 10233876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine alpha s1-casein gene sequences direct high level expression of human granulocyte-macrophage colony-stimulating factor in the milk of transgenic mice.
    Uusi-Oukari M; Hyttinen JM; Korhonen VP; Västi A; Alhonen L; Jänne OA; Jänne J
    Transgenic Res; 1997 Jan; 6(1):75-84. PubMed ID: 9032980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the erythropoietin-induced erythroid differentiation by granulocyte-macrophage colony-stimulating factor in the human UT-7 cell line is not due to a negative regulation of the erythropoietin receptor.
    Hermine O; Dubart A; Porteux F; Mayeux P; Titeux M; Dumenil D; Vainchenker W
    Blood; 1996 Mar; 87(5):1746-53. PubMed ID: 8634420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte macrophage-colony stimulating factor: evidence of a previously unknown anabolic effect of erythropoietin?
    Fatouros M; Dalekos GN; Mylonakis E; Vekinis G; Kappas AM
    J Lab Clin Med; 1999 Mar; 133(3):253-9. PubMed ID: 10072257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of recombinant human GM-CSF-EPO hybrid proteins: in vitro biological characterization.
    Coscarella A; Carloni C; Liddi R; Mauro S; Novelli S; Mele A; Masella B; Valtieri M; De Santis R
    Eur J Haematol; 1997 Oct; 59(4):238-46. PubMed ID: 9338622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.
    Halpern W; Riccobene TA; Agostini H; Baker K; Stolow D; Gu ML; Hirsch J; Mahoney A; Carrell J; Boyd E; Grzegorzewski KJ
    Pharm Res; 2002 Nov; 19(11):1720-9. PubMed ID: 12458679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis.
    Battaglia A; Fattorossi A; Pierelli L; Bonanno G; Marone M; Ranelletti FO; Coscarella A; De Santis R; Bach S; Mancuso S; Scambia G
    Exp Hematol; 2000 May; 28(5):490-8. PubMed ID: 10812238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response to a single intramuscular injection of recombinant adeno-associated virus-erythropoietin in monkeys.
    Rudich SM; Zhou S; Srivastava R; Escobedo JA; Perez RV; Manning WC
    J Surg Res; 2000 May; 90(2):102-8. PubMed ID: 10792948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
    Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
    J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the efficacy of mast cell growth factor (c-kit ligand) in vitro as well as in vivo.
    Hintz-Obertreis P; Weinmann E; Seiler FR
    Behring Inst Mitt; 1991 Dec; (90):14-22. PubMed ID: 1724901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice.
    Yang J; Sun J; Castellanos DM; Pardridge WM; Sumbria RK
    Mol Pharm; 2020 Aug; 17(8):2831-2839. PubMed ID: 32579360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The induction of interleukin-6 (IL-6) and colony-stimulating factors (CSFs) by FK565 and its thrombopoietic activity following in vivo administration.
    Maeda M; Suzuki S; Ohtsuka K; Satoh S; Nishigaki F; Shimomura K; Imai Y; Niwa M; Kohsaka M
    Biol Pharm Bull; 1994 Feb; 17(2):173-9. PubMed ID: 7515742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.